Two NGOs have challenged the patent protection of a leukaemia drug produced by Swiss pharmaceutical company Novartis. They complain that the patent on the drug Kymriah allows Novartis to charge inflated prices for its use on patients.
This content was published on
1 minute
swissinfo.ch/mga
Pressure groups Public Eye and Médecins du Monde have filed their objection to the European patent office in Munich. They claim that Kymriah was not invented by Novartis because the research behind the drug was carried out by public institutions.
The medicament, which is used to treat leukaemia and lymph gland cancer on patients who have not responded to previous therapies, costs CHF370,000 ($375,000) per infusion. This makes it the most expensive drug in Switzerland, say the NGOs.
If the NGOs succeed in nullifying the patent, Novartis will still be able to sell the drug but without having a monopoly that allows it to charge more.
The decisions of the Munich patent authority are binding on Switzerland despite not being a member state of the European Union. Novartis told the Swiss news agency Keystone-SDA that its lawyers are analysing the legal challenge.
More
More
How can a drug cost $2.1 million?
This content was published on
US authorities have approved a $2.1 million gene therapy, making it the most expensive drug ever. Can such a price tag be justified?
Train vs plane: would you take a direct train between London and Geneva?
Eurostar is planning to run direct trains from Britain to Germany and Switzerland from the early 2030s. Would you favour the train over the plane? If not, why not?
Zurich arbitration authority rules in favour of tenants of ‘Sugus Houses’
This content was published on
A conciliation authority says the terminations of 105 flat leases in the so-called "Sugus Houses" in the centre of Zurich were abusive. The tenants therefore do not have to move out - at least for the time being.
This content was published on
Visitors to Switzerland spent CHF19.6 billion ($23.9 billion) last year, a 2.2% rise compared to the previous year, the Federal Statistical Office (FSO) said on Monday.
This content was published on
Despite the current tense economic situation, Swiss consumer sentiment remains positive. The Swiss spent more money in May than the previous year, particularly on restaurant visits and leisure activities, as shown by the latest figures released by PostFinance.
This content was published on
A bear killed four sheep in the Lower Engadine region near Scuol, canton Graubünden, last week. This was the first bear attack on local livestock in four years.
This content was published on
Experts believe that economic development in Switzerland will be weaker in 2026 than the forecasts made three months ago. They have also lowered their predictions for the current year.
This content was published on
Fewer people in Switzerland have a religious affiliation and the proportion who practice their religion regularly is steadily declining, a survey finds.
Study: trees have major cooling effect even in extreme heat
This content was published on
Plane trees in cities have an important cooling effect even in extreme heat, according to a new study by the Swiss Federal Institute for Forest, Snow and Landscape Research (WSL).
EPFL launches digitised version of Battle of Murten panorama
This content was published on
To mark the anniversary of the Battle of Murten on 22 June 1476, the Federal Institute of Technology Lausanne (EPFL) has launched a website that offers the public an immersive experience of the huge panorama painting of the historic battle.
77th Swiss Gymnastics Festival praised for ‘positive energy’
This content was published on
The 77th Federal Gymnastics Festival drew to a close on Sunday in Lausanne, after eleven days of popular celebration and sporting performances.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Swiss healthcare costs expected to rise well above inflation
This content was published on
On Monday, SantésuisseExternal link outlined the main reasons for the expected increases in health insurance policies. It predicts a 6% rise in physiotherapy treatments, the same greater demand for care for the elderly and in nursing homes and 5% extra medical diagnostics being performed in laboratories. In addition, insurers expect costs to rise to a…
Generic drugs remain twice as expensive in Switzerland
This content was published on
Drug prices in Switzerland remain higher than in other major European markets, especially when it comes to generic drugs, which are twice as expensive in Switzerland as elsewhere.
This content was published on
Curing cancer for the masses could be challenging if healthcare systems are crippled by rapidly rising cancer drug prices.
WHO adopts watered-down resolution on drug transparency
This content was published on
The World Health Organization (WHO) has adopted a resolution to improve transparency on drug prices but some people say it doesn't go far enough.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.